Printer Friendly

BIO-IMAGING TECHNOLOGIES, INC. WINS NEW BUSINESS

 WEST TRENTON, N.J., May 19 /PRNewswire/ -- Bio-Imaging Technologies, Inc. (NASDAQ: BITI), a company providing medical imaging-related research and consulting services to the pharmaceutical, biotechnology and medical device industries, announced today that the company has signed agreements to conduct projects for two new clients: Marion Merrell Dow, Inc. of Kansas City, Mo.,(NYSE: MMD) and Diatech, Inc., a privately held biotechnology company based in Londonderry, N.H. The initial value of these new projects exceeds $240,000.
 Bio-Imaging Technologies will provide imaging-related services for the newly announced clients using the company's proprietary medical imaging and image-processing technology. Bio-Imaging Technologies will assist each client through application of computerized image analysis techniques to evaluate drug effects or diagnostic utility.
 Diatech, a company specializing in the research and development of peptide-based imaging agents for cancer, inflammation and cardiovascular disease, selected Bio-Imaging Technologies to provide clinical development, core imaging laboratory and regulatory support services for several agents currently under development by Diatech.
 Marion Merrell Dow, a leading pharmaceutical company, contracted with Bio-Imaging Technologies for an unspecified project.
 James J. Conklin, MD, CEO and chairman of Bio-Imaging Technologies, said, "These new contracts broaden our range of imaging applications to include a wider variety of agents for the diagnosis of cancer, cardiovascular disease and other indications. We believe that recent news reports on the use of MRI and other imaging modalities to evaluate drug effects suggest that our company is on the leading edge of an important technology trend in drug development."
 Bio-Imaging Technologies, Inc. of West Trenton, provides specialized research and consulting services to pharmaceutical, biotechnology and medical device companies. The company applies advanced technologies such as magnetic resonance imaging, radionuclide imaging and computer- assisted image analysis to visualize and measure drug and medical device effects during the clinical development and pre-clinical testing process. The company's technology can help to accelerate the development and regulatory review of new therapeutic and diagnostic agents and devices by providing more precise analyses from a smaller number of study subjects. The company also applies its technology to develop interactive regulatory submissions and image-based medical communications.
 /delval/
 -0- 5/19/93
 /CONTACT: William L. Robbins, director of Business Development, Bio-Imaging Technologies, 609-883-2000/
 (BITI MMD)


CO: Bio-Imaging Technologies, Inc.; Marion Merrell Dow, Inc.; Diatech,
 Inc. ST: New Jersey IN: CPR SU: CON


CC -- PH001 -- 0089 05/19/93 07:37 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 19, 1993
Words:390
Previous Article:STEEL CAN RECYCLING INSTITUTE BECOMES STEEL RECYCLING INSTITUTE; NAME CHANGE REFLECTS EXPANDED VISION
Next Article:MICROPROBE AWARDED SBIR GRANT TO EVALUATE RAPID TEST FOR ANTIBIOTIC RESISTANCE
Topics:


Related Articles
BIO-IMAGING TECHNOLOGIES, INC. CEO JAMES J. CONKLIN, M.D., TO SPEAK AT MASSACHUSETTS GENERAL HOSPITAL ON BRAIN IMAGING AND DRUG DEVELOPMENT
BIO-IMAGING TECHNOLOGIES, INC. CEO JAMES J. CONKLIN, MD ELECTED AS A REGIONAL FINALIST IN 1993 ENTREPRENEUR OF THE YEAR AWARDS
BIO-IMAGING TECHNOLOGIES, INC. ANNOUNCES THIRD QUARTER, 1994 RESULTS
Bio-Imaging Technologies, Inc. Announces Record First Quarter Results
Bio-Imaging Technologies, Inc. Announces Contract With SEQUUS Pharmaceuticals, Inc.
Bio-Imaging Technologies, Inc. Announces Contract with Pharmacyclics, Inc.
Bio-Imaging Technologies, Inc. Announces Contract with Diatide, Inc.
Bio-Imaging Technologies, Inc. Announces Participation in NPS Phase III Osteoporosis Trial.
Bio-Imaging Technologies Acquires Quintiles' Intelligent Imaging Business.
Perlegen Sciences Wins Bio-IT world 2003 Best Practices Award.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters